CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) shares dropped 4% during trading on Monday . The stock traded as low as $0.14 and last traded at $0.14. Approximately 2,274,842 shares were traded during trading, a decline of 11% from the average daily volume of 2,542,370 shares. The stock had previously closed at $0.15.
CytoDyn Trading Down 4.0 %
The firm has a fifty day moving average of $0.15 and a 200 day moving average of $0.15. The company has a market capitalization of $150.77 million, a P/E ratio of -2.85 and a beta of 0.13.
CytoDyn (OTCMKTS:CYDY - Get Free Report) last posted its earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 EPS for the quarter.
About CytoDyn
(
Get Free Report)
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CytoDyn, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.
While CytoDyn currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
